Lonza | LONN - Operating Expenses


Lonza reported CHF2.9B in Operating Expenses for its fiscal semester ending in June of 2025.





Operating Expenses Change Date
Akzo Nobel EUR 2.13B 23M Mar/2026
Alcon AG USD 2.41B 4M Mar/2026
Almirall EUR 517.4M 32K Dec/2025
AstraZeneca USD 8.18B 4.35B Mar/2026
BASF EUR 14.62B 410M Mar/2026
Bayer EUR 9.88B 452M Mar/2026
Beiersdorf EUR 4.16B 212M Dec/2025
Covestro EUR 3.24B 5.46B Dec/2025
Demant DKK 9.63B 241M Dec/2025
Fresenius EUR 5.25B 337M Dec/2025
Fresenius Medical Care EUR 4.34B 63M Mar/2026
Geberit CHF 581.3M 1.3M Dec/2025
Genmab DKK 798M 235M Dec/2025
Givaudan CHF 3B 107M Dec/2025
GlaxoSmithKline GBP 5.34B 1.85B Mar/2026
GN Store Nord DKK 2.16B 1.94B Mar/2026
Hikma Pharmaceutical USD 1.34B 702M Dec/2025
Johnson Matthey GBP 7.02B 1.81B Jun/2026
Merck EUR 4.09B 687M Mar/2026
Novartis USD 9.29B 507M Mar/2026
Philips EUR 3.6B 775M Mar/2026
Roche Holding CHF 21.01B 10.84B Dec/2025
Sanofi EUR 9.31B 1.2B Mar/2026
Sika AG CHF 4.8B 78.3M Dec/2025
Smith & Nephew USD 2.52B 84M Dec/2025
Solvay EUR 1.02B 10M Mar/2026
UCB EUR 2.96B 196M Dec/2025